Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Jonsson Comprehensive Cancer Center
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03425461CT.gov Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma | — | Terminated | — | — | — |
NCT03326258CT.gov Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | — | Withdrawn | — | — | — |
NCT02910700CT.gov Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | — | Active Not Recruiting | — | — | — |
NCT02581930CT.gov Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma | — | Active Not Recruiting | — | — | — |
NCT02650635CT.gov TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | — | Terminated | — | — | — |
NCT02304458CT.gov Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | — | Completed | — | — | — |
NCT02097225CT.gov Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | — | Terminated | — | — | — |
NCT01989585CT.gov Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | — | Active Not Recruiting | — | — | — |
NCT01970527CT.gov Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma | — | Terminated | — | — | — |
NCT02158520CT.gov Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery | — | Completed | — | — | — |
Show 19 more trialsShow fewer
NCT01727076CT.gov Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer | — | Completed | — | — | — |
NCT01638533CT.gov Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | — | Completed | — | — | — |
NCT01522820CT.gov Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | — | Completed | — | — | — |
NCT01364051CT.gov Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies | — | Active Not Recruiting | — | — | — |
NCT01303341CT.gov Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma | — | Active Not Recruiting | — | — | — |
NCT01196416CT.gov Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma | — | Completed | — | — | — |
NCT01131234CT.gov Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00861913CT.gov Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery | — | Completed | — | — | — |
NCT00661336CT.gov A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma | — | Withdrawn | — | — | — |
NCT00514085CT.gov Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma | — | Completed | — | — | — |
NCT00565968CT.gov Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg | — | Completed | — | — | — |
NCT00526149CT.gov BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT00811759CT.gov Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma | — | Unknown | — | — | — |
NCT00492440CT.gov Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer | — | Terminated | — | — | — |
NCT00667901CT.gov Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery | — | Terminated | — | — | — |
NCT00436410CT.gov Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer | — | Completed | — | — | — |
NCT00387751CT.gov Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma | — | Completed | — | — | — |
NCT00110019CT.gov Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT00602199CT.gov ABT-510 in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cutaneous Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cediranib (this asset) | Jonsson Comprehensive Cancer Center | P3 | BB · 70 |
| Alpha-Interferon | MIPO Clinic | P3 | BBB |
| TIL | City of Hope Medical Center | P2 | BBB |
| Dacarbazine | Linnaeus Therapeutics, Inc. | P3 | BBB |
| Tyrosinase Peptide | University of Southern California | P3 | BBB |
| Cis-Diamminedichloroplatinum Ii | MIPO Clinic | P3 | BBB |
| Multi-Epitope Melanoma Peptide Vaccine | Craig L Slingluff, Jr | P2 | BB |
| Nivestim | Vastra Gotaland Region | P3 | BB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
+42 more in the Cutaneous Melanoma cohort
Other indications for Cediranib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gliosarcoma | — | P2 | BBB · 76 |
| Metastatic Melanoma | — | P2 | BBB · 73 |
| Adult Glioblastoma | — | P2 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cediranib in Cutaneous Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cediranib-cutaneous-melanoma-77255
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →